# Study of LY2409021 in Participants With Type 1 Diabetes

> **NCT01640834** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 20 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** LY2409021
- **DRUG:** Placebo
- **DRUG:** Glucagon

## Key facts

- **NCT ID:** NCT01640834
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01640834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01640834, "Study of LY2409021 in Participants With Type 1 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01640834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*